Search results for "macular edema"

showing 10 items of 62 documents

Retrograde Maculopathy in Patients With Glaucoma

2017

PURPOSE Macular optical coherence tomography (OCT) analysis can be used for quantitative measures of optic nerve atrophy at a location far from the optic nerve head. This recently led to the finding of microcystic macular edema (MME), that is vacuolar inclusions in the macular inner nuclear layer, in some glaucoma patients. The involvement of individual retinal layers is yet unclear in glaucoma. In this study we systematically investigated glaucoma-induced changes in macular layers to evaluate whether glaucoma-associated damage extends beyond the macular ganglion cell layer. PATIENTS AND METHODS We included 218 consecutive patients and 282 eyes with confirmed primary open-angle glaucoma or …

MaleRetinal Ganglion Cellsmedicine.medical_specialtygenetic structuresOptic DiskVisual AcuityNerve fiber layerGlaucoma610 Medicine & healthExfoliation SyndromeMacular EdemaRetina03 medical and health sciencesNerve Fibers0302 clinical medicineOphthalmologymedicineHumans610 Medicine & healthMacular edemaGanglion cell layerIntraocular PressureAgedRetrospective StudiesAged 80 and overRetinabusiness.industryMiddle Agedmedicine.diseaseeye diseasesOphthalmologyCross-Sectional Studiesmedicine.anatomical_structureInner nuclear layer030221 ophthalmology & optometryOptic nerveVisual Field TestsMaculopathyFemalesense organsbusinessGlaucoma Open-AngleTomography Optical Coherence030217 neurology & neurosurgeryJournal of Glaucoma
researchProduct

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat stu…

2020

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT centr…

MaleTime FactorsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityDexamethasone0302 clinical medicinedexamethasone implantDrug Implantsdiabetescataract surgeryGeneral MedicineTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalecataract surgery; dexamethasone implant; diabetes; diabetic macular oedemamedicine.symptomTomography Optical Coherencemedicine.drugmedicine.medical_specialtyCataract ExtractionCataractMacular Edema03 medical and health sciencesOphthalmologyDiabetes mellitusmedicineHumansAdverse effectGlucocorticoidsDexamethasoneAgedRetrospective StudiesDiabetic RetinopathySettore MED/30 - Malattie Apparato Visivobusiness.industryRetrospective cohort studyCataract surgerymedicine.diseaseeye diseasesOphthalmologydiabeteConcomitant030221 ophthalmology & optometryImplantbusiness030217 neurology & neurosurgeryFollow-Up StudiesActa Ophthalmologica
researchProduct

How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010–2016

2020

Purpose. To describe intravitreal anti-VEGF drug and dexamethasone use in four Italian regions. Methods. Four regional claims databases were used to measure drug prevalence, compare dosing intervals to those recommended in the summary of product characteristics (SPC), and identify switchers. Bilateral treatment and diabetic macular edema (DME) coding algorithms were validated, linking claims with a sample of prospectively collected ophthalmological data. Results. Overall, 41,836 patients received ≥1 study drug in 2010–2016 (4.8 per 10,000 persons). In 2016, anti-VEGF drug use ranged from 0.8 (Basilicata) to 5.7 (Lombardy) per 10,000 persons while intravitreal dexamethasone use ranged from 0…

MaleVascular Endothelial Growth Factor A0301 basic medicineintravitrealAngiogenesis Inhibitorsalgorithm.0302 clinical medicineMedicineSummary of Product Characteristicsmedia_commonAged 80 and overDrug ImplantsvalidationLaser CoagulationRGeneral MedicineMiddle AgedItalyanti-VEGF030220 oncology & carcinogenesisMedicineFemaleclinical dataoriginal articleResearch Articlemedicine.drugDrugmedicine.medical_specialtyArticle Subjectmedia_common.quotation_subjectMEDLINEdexamethasonePharmacyMacular EdemaGeneral Biochemistry Genetics and Molecular BiologyInsurance Claim Review03 medical and health sciencesRanibizumabInternal medicineHumansDosingDexamethasoneAgedDiabetic RetinopathyGeneral Immunology and MicrobiologySettore MED/30 - Malattie Apparato Visivobusiness.industryclaims database030104 developmental biologydrug utilisationMacular Edema; Ranibizumab; Laser CoagulationImplantRanibizumabbusinessBioMed Research International
researchProduct

Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group.

2014

Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies. Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuva…

MaleVascular Endothelial Growth Factor ATriamcinolone acetonideVisual acuitygenetic structuresmedicine.medical_treatmentExtração de catarataVisual AcuityIntraocular lensCuidados intraoperatóriosAngiogenesis InhibitorsTriamcinolonelcsh:OphthalmologyLens Implantation IntraocularDiabetic retinopathyAntibodies monoclonalAged 80 and overGeneral MedicineDiabetic retinopathyMiddle AgedMulticenter studyBevacizumabTreatment OutcomeCataract extractionChemotherapy AdjuvantEstudo multicêntricoIntravitreal InjectionsFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabAntibodies Monoclonal HumanizedCataractMacular EdemaIntraoperative careOphthalmologyEdema macularmedicineAnticorpos monoclonaisHumansMacular edemaGlucocorticoidsAgedRetrospective StudiesMacular edemaDiabetic RetinopathyIntraoperative CarePhacoemulsificationbusiness.industryRetinopatia diabéticaPhacoemulsificationCataract surgeryFacoemulsificaçãomedicine.diseaseSurgeryImplante de lente intraocularOphthalmologyLens implantation intraocularlcsh:RE1-994businessFollow-Up StudiesArquivos brasileiros de oftalmologia
researchProduct

Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southe…

2022

Describe drug utilisation and clinical outcomes of intravitreal anti-VEGF drug and dexamethasone use in the real-world setting in Southern Italy using data from multi-centre study of retinal disease. Clinical data of retinal disease patients treated with anti-VEGF drugs and dexamethasone implant in 6 out-patient ophthalmology centres from Southern Italy were collected by means of an electronic case report form. Patients receiving at least one intravitreal injection/implant of the study drugs were followed for up to two years and described in terms of demographics and clinical characteristics. Drug utilisation patterns were described. A sign-rank test was used to compare clinical data on vi…

MaleVascular Endothelial Growth Factor Agenetic structuresPharmacology &ltPHARMACOLOGY diabetic macular edema &ltbiostatisticsAngiogenesis InhibitorsDexamethasoneMacular DegenerationCATARACTRetinal DiseasesRanibizumabRetinal Vein OcclusionHumansProspective StudiesRETINAAgedAged 80 and overPharmacologySettore MED/30 - Malattie Apparato Visivopathologic myopiaGeneral MedicineMiddle AgedBevacizumabOphthalmologyLENSRETINA epidemiology / biostatistics pathologic myopia retina - medical therapies &ltIntravitreal InjectionsPharmacology diabetic macular edema RETINA epidemiology biostatisticsLENSCATARACTpathologic myopiaFemaleepidemiologydiabetic macular edemaEuropean Journal of Ophthalmology
researchProduct

Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular ede…

2013

To evaluate the anatomical and functional outcomes at 24 months in patients with diffuse diabetic macular edema treated with primary intravitreal bevacizumab (IVB) plus grid laser photocoagulation (GLP) or primary IVB alone or GLP alone.Retrospective, interventional, comparative, multicenter study. We included in this analysis 141 eyes of 120 patients with diffuse diabetic macular edema treated with primary IVB alone (Group A), 120 eyes of 94 patients with GLP therapy (Group B), and 157 eyes of 104 patients treated with IVB plus GLP (Group C).In all 3 groups, the authors observed improvement of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity from baseline to 24-month…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresDiabetic macular edemaVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMacular EdemaOphthalmologymedicineHumansIn patientIntravitreal bevacizumabRetrospective StudiesRetinaDiabetic RetinopathyLaser Coagulationbusiness.industryGeneral MedicineMiddle AgedCombined Modality Therapyeye diseasesbody regionsBevacizumabOphthalmologymedicine.anatomical_structureTreatment OutcomeIntravitreal InjectionsFemalesense organsbusinessTomography Optical CoherenceRetina (Philadelphia, Pa.)
researchProduct

Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers

2019

Purpose: To analyse the effects of intravitreal dexamethasone implant (DEX) in patients with diabetic macular oedema (DME) unresponsive to ranibizumab treatment, in relation to the inflammatory optical coherence tomography (OCT) retinal features, subfoveal neuroretinal detachment (SND) and hyperreflective retinal spots (HRS). Methods: Patients with DME poorly responsive to three injections of ranibizumab were treated with DEX. Best-corrected visual acuity (BCVA) and central macula thickness (CMT, measured by Spectralis SD-OCT) were assessed at baseline and at 1, 3, and 6 months. Results: Overall, 44 eyes were included in the study. In the whole group, mean BCVA (baseline 51.5 ± 8.3 letters)…

MaleVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsDrug Implantchemistry.chemical_compound0302 clinical medicineGlucocorticoidMacula LuteaProspective StudiesFluorescein AngiographyProspective cohort studyTomographyDrug Implantsmedicine.diagnostic_testGeneral MedicineDiabetic retinopathyDrug ToleranceFluorescein angiographyTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalemedicine.symptomDrugTomography Optical Coherencemedicine.drugAngiogenesis InhibitorHumanmedicine.medical_specialtyFundus Oculibest-corrected visual acuity; dexamethasone; diabetes retinopathy; diabetic macular oedema; optical coherence tomography; ranibizumab; Aged; Angiogenesis Inhibitors; Dexamethasone; Diabetic Retinopathy; Dose-Response Relationship Drug; Drug Implants; Drug Tolerance; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Glucocorticoids; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Prospective Studies; Ranibizumab; Tomography Optical Coherence; Treatment Outcome; Visual AcuitydexamethasoneMacular EdemaFollow-Up StudieDose-Response Relationship03 medical and health sciencesOphthalmologyRanibizumabmedicineHumansMacular edemaGlucocorticoidsDexamethasoneAgedbest-corrected visual acuity; dexamethasone; diabetes retinopathy; diabetic macular oedema; optical coherence tomography; ranibizumab; Aged; Angiogenesis Inhibitors; Dexamethasone; Diabetic Retinopathy; Dose-Response Relationship; Drug; Drug Implants; Drug Tolerance; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Glucocorticoids; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Prospective Studies; Ranibizumab; Tomography; Optical Coherence; Treatment Outcome; Visual Acuityoptical coherence tomographyDiabetic RetinopathyDose-Response Relationship Drugbusiness.industryIntravitreal InjectionRetinalmedicine.diseaseeye diseasesOphthalmologyProspective StudiechemistryOptical Coherence030221 ophthalmology & optometrysense organsRanibizumabbusinessdiabetes retinopathy030217 neurology & neurosurgerybest-corrected visual acuityFollow-Up Studies
researchProduct

DEXAMETHASONE INTRAVITREAL IMPLANT VS RANIBIZUMAB IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRACHYTHERAPY FOR CHOROIDAL MELANOMA

2017

PURPOSE To evaluate the efficacy of an intravitreal dexamethasone (Dex) implant 0.7 mg compared with intravitreal ranibizumab (Ra) for the treatment of radiation maculopathy with macular edema secondary to plaque brachytherapy in choroidal melanoma. METHODS Eight patients were treated with intravitreal Ra, and eight patients received the Dex intravitreal implant. Visual acuity and foveal thickness were evaluated using spectral domain optical coherence tomography. RESULTS The mean calculated irradiation to the fovea and mean times from brachytherapy to maculopathy development did not differ significantly between groups. In the Ra group, a mean 7.8 ± 3.9 injections were given and the mean fol…

MaleVisual acuitygenetic structuresmedicine.medical_treatmentBrachytherapyOcular hypertensionAngiogenesis InhibitorsDrug Implant0302 clinical medicineGlucocorticoidDexamethasone Intravitreal ImplantRadiation InjurieMelanomaDrug ImplantsChoroid NeoplasmsGeneral MedicineMiddle AgedIntravitreal InjectionsDrug Therapy CombinationFemalemedicine.symptommedicine.drugAngiogenesis InhibitorHumanmedicine.medical_specialtyBrachytherapydexamethasone03 medical and health sciencesradiation maculopathyOphthalmologyRanibizumabmedicineHumanschoroidal melanomaRadiation InjuriesGlucocorticoidsMacular edemaDexamethasoneAgedRetrospective Studiesmacular edemabusiness.industryIntravitreal Injectionmedicine.diseaseeye diseasesOphthalmology030221 ophthalmology & optometryMaculopathyRanibizumabbusinessChoroid Neoplasm030217 neurology & neurosurgery
researchProduct

Prophylaxis of Pseudophakic Cystoid Macular Edema with Intraoperative Pegaptanib

2011

The purpose of this study was to determine the efficacy of an intraoperative intravitreal pegaptanib injection during phacoemulsification in preventing the development of pseudophakic cystoid macular edema (CME) following cataract surgery.This prospective, controlled pilot study was carried out at the Department of Ophthalmology, Nuevo Hospital Universitario y Politécnico La Fe, Valencia (Spain). Five hundred patients with cataract and healthy retina were included in the study. Patients were assigned in a 1:1 ratio to receive an intraoperative intravitreal pegaptanib injection (n=250) or not (control group, n=250) associated with standardized phacoemulsification surgery and postoperative tr…

Malemedicine.medical_specialtyPseudophakiagenetic structuresPegaptanibmedicine.medical_treatmentPilot ProjectsMacular EdemaHospitals UniversityPostoperative treatmentOphthalmologymedicineHumansPharmacology (medical)Prospective StudiesMacular edemaAgedAged 80 and overPharmacologyPhacoemulsificationSurgical complicationbusiness.industryIncidence (epidemiology)Outcome measuresPhacoemulsificationAptamers NucleotideCataract surgerymedicine.diseaseeye diseasesSurgeryOphthalmologyTreatment OutcomeSpainIntravitreal InjectionsFemalesense organsbusinessTomography Optical CoherenceFollow-Up Studiesmedicine.drugJournal of Ocular Pharmacology and Therapeutics
researchProduct

Local safety of repeated intravitreal Ozurdex

2013

Sir, The article entitled ‘Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion'1 highlights the significant cataract progression in eyes receiving more than one Ozurdex implant. We retrospectively reviewed the charts of all patients with macular edema secondary to retinal vein occlusion (RVO) refractory to current therapies and treated with Ozurdex from April 2010 until March 2012. The mean age of patients with branch RVO (n=33) was 72.4. In eyes receiving a second Ozurdex implant, four out of the five phakic eyes showed progression of cataract requiring surgery. We registered one case of anterior chamber migration resulting in a bu…

Malemedicine.medical_specialtyRetinal Veingenetic structuresDexamethasoneMacular EdemaRefractoryOphthalmologyCorrespondenceRetinal Vein OcclusionOcclusionmedicineHumansIn patientGlucocorticoidsMacular edemaDexamethasonebusiness.industryIncidence (epidemiology)medicine.diseaseeye diseasesSurgeryOphthalmologyFemalesense organsImplantbusinessmedicine.drugEye
researchProduct